Rexahn Pharma presents update of ongoing phase IIa clinical trial of RX-3117 in Metastatic
Rexahn Pharma announced an update on the safety and efficacy of RX-3117 in an ongoing Phase IIa clinical trial in metastatic pancreatic cancer. Patients enrolled into stage 1 of the clinical trial had actively progressing disease with 55% of them having received 4 or more prior cancer therapies. January 20, 2017